Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research
Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study
Related
- Cost-effectiveness of disitamab vedotin plus toripalimab versus chemotherapy alone as first-line treatment for HER2-overexpressing advanced urothelial carcinoma: a cost-effectiveness analysis from the Chinese healthcare system perspective
- Efficacy and safety of neoadjuvant chemotherapy with toripalimab in locally advanced nasopharyngeal carcinoma: a phase II trial and biological correlate analysis
- Genomic alterations associated with response to neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
- First-line toripalimab in combination with platinum-doublet chemotherapy for advanced B3 thymoma and thymic carcinoma: an open-label prospective phase Ⅱ trial.
- PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
BibTeX
@article{anon2026toripalimab,
title = {{Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study}},
journal = {Translational Lung Cancer Research},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13657877},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study
PY - 2026
DA - 2026/08/31
JO - Translational Lung Cancer Research
UR - https://europepmc.org/article/PMC/PMC13657877
SN - 2218-6751
ER -